| Â | Model 1 | Model 2 | Model 3 |
|---|
30-day mortality | β (95% CI) | P-value | β (95% CI) | P-value | β (95% CI) | P-value |
|---|
Day | 0.03 (−1.06,0.23) | 0.770 | 0.03 (0.16,0.22) | 0.780 | 0.03 (−0.17,0.23) | 0.800 |
Death | 4.02 (1.40,6.63) | 0.003 | 3.88 (1.17,6.59) | 0.005 | 4.59 (1.61,7.58) | 0.003 |
Day × death | 1.01 (0.73,1.29) |  < 0.001 | 1.01 (0.73,1.29) |  < 0.001 | 1.03 (0.75,1.31) |  < 0.001 |
- Time, the mean daily increase in NLR over time (1–14 days) in the survival group; death, the mean difference in NLR between the survivor and non-survivor groups at admission; death × day, daily rise in NLR, specifically within the non-survivor group compared with the survivor group
- Model 1, not adjusted for any variables. Model 2, adjusted for age and sex. Model 3, adjusted for age, sex, duration, smoking, mechanic’s hand, heliotrope rash, Gottron’s sign/papules, V sign, Shawl sign, periungual erythema, Raynaud phenomenon, skin ulcer, muscle weakness, arthritis, Ro52, fever, ANA, RA, ALB, ALT, AST, CK, LDH, CRP, ESR, and WBC count
- Abbreviations: ALB albumin, ALT alanine aminotransferase, ANA antinuclear antibody, AST aspartate aminotransferase, CI confidence interval, CK creatine kinase, CRP C-reactive protein, DM-ILD dermatomyositis with interstitial lung disease, ESR erythrocyte sedimentation rate, GAMM Generalized Additive Mixed Model, HR hazard ratio, LDH lactate dehydrogenase, NLR neutrophil-to-lymphocyte ratio, RA rheumatoid arthritis, WBC white blood cell count
